Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$11.5B
sum of reported positions
Reported positions
84
Changes vs prior quarter
51
17 new · 18 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 63 measured positions in 8 quarters, the typical new or larger position finished −2.9 pts against the S&P 500 and 44% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 10.3M | $2.74B | 23.8% | |
| 28.9M | $792M | 6.9% | |
| 6.67M | $740M | 6.4% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $9.44B | $11.5B |
| Positions | 85 | 84 |
| Biggest line | — | Ascendis Pharma A 24% |
| 11.5M |
| $667M |
| 5.8% |
| 9.91M | $436M | 3.8% |
| 12.2M | $390M | 3.4% |
| 8.39M | $341M | 3.0% |
| 9.55M | $324M | 2.8% |
| 7.81M | $287M | 2.5% |
| 7M | $234M | 2.0% |
| 7.26M | $215M | 1.9% |
| 7.69M | $208M | 1.8% |
| 7.64M | $205M | 1.8% |
| 2.45M | $179M | 1.6% |
| 8.02M | $179M | 1.6% |
| 18M | $174M | 1.5% |
| 11.2M | $172M | 1.5% |
| 23.6M | $160M | 1.4% |
| 15.8M | $158M | 1.4% |
WAVE LIFE SCIENCES LTD | 27M | $157M | 1.4% |
NUVALENT INC-A | 1.25M | $154M | 1.3% |
| 1.13M | $151M | 1.3% |
| 1.55M | $148M | 1.3% |
| 11.3M | $147M | 1.3% |
| 12M | $120M | 1.0% |
Faeth Therapeutics (FTH)
722K shares
Aura Biosciences (AURA)
2.5M shares
Seaport Therapeutics (SPTX)
700K shares
Adicet Bio (ACET)
1.18M → 933K shares (−21%)
JATT II ACQUISITION CORP
500K shares
AMANAT ACQUISITION CORP CL A
375K shares
Werewolf Therapeutics (HOWL)
6.68M → 2.39M shares (−64%)
Palatin Technologies (PTN)
70K → 62K shares (−11%)
ASCENDIS PHARMA A/S - ADR
10.3M shares in Q1 2026
Fulcrum Therapeutics (FULC)
6.05M shares in Q1 2026
Sarepta Therapeutics (SRPT)
3.9M shares in Q1 2026
Design Therapeutics (DSGN)
2.97M shares in Q1 2026
Relmada Therapeutics (RLMD)
2.95M shares in Q1 2026
Dianthus Therapeutics, Inc. (DNTH)
2.61M shares in Q1 2026
Olema Pharmaceuticals (OLMA)
2.6M shares in Q1 2026
Spyre Therapeutics (SYRE)
1.62M shares in Q1 2026
Contineum Therapeutics (CTNM)
1.3M shares in Q1 2026
Atrium Therapeutics (RNA)
864K shares in Q1 2026
Travere Therapeutics (TVTX)
747K shares in Q1 2026
Sutro Biopharma (STRO)
715K shares in Q1 2026
Grail (GRAL)
428K shares in Q1 2026
Praxis Precision Medicines (PRAX)
374K shares in Q1 2026
Hinge Health (HNGE)
365K shares in Q1 2026
Inspire Medical Systems, Inc. (INSP)
326K shares in Q1 2026
Maplight Therapeutics (MPLT)
248K shares in Q1 2026
